References
  1. Jensen EA, Demauro SB, Kornhauser M, Aghai ZH, Greenspan JS, Dysart KC. Effects of multiple ventilation courses and duration of mechanical ventilation on respiratory outcomes in extremely low-birth-weight infants. JAMA Pediatr . 2015; 169 : 1011-1017.
  2. Gizzi CC, Moretti C, Agostino R. Weaning from mechanical ventilation.J. Matern. Fetal. Neonatal. Med. 2011; 24 : 61-63.
  3. Gupta S, Prasanth K, Chen CM, Yeh TF. Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. Int. J. Pediatr . 2012; 2012 : p. 315642.
  4. Kamlin COF, Davis PG, Morley CJ. Predicting successful extubation of very low birthweight infants. Arch. Dis. Child. Fetal. Neonatal. Ed . 2006; 91 : 180-183.
  5. Ng PC. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Arch. Dis. Child.1993; 68 : 330-336.
  6. Cheong JLY, Doyle LW. Long-term effects of postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia : Balancing the risks and benefits. Semin. Fetal. Neonatal. Med . 2019; 24:197-201
  7. Cuna A,Govindarajan S, Oschman A, Dai H, Brophy K, Norberg M, Truong W. A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants. J. Perinatol . 2017; 37 : 301-305.
  8. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology. 2010; 98 : 111-117.
  9. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst. Rev . 2017; 10 : CD001145
  10. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants.Cochrane Database Syst. Rev. 2009; 1 : CD001145
  11. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N. Engl. J. Med. 2004; 350 : 1304-1313.
  12. Doyle LW, Cheong JLY. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia- Who might benefit? Semin. Fetal. Neonatal. Med . 2017; 22 : 290-295
  13. Grier DG, Halliday HL. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin. Neonatol . 2003; 8 : 83-91.
  14. Doyle LW, Ehrenkranz RA, Halliday HL, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: Effect modification by risk of bronchopulmonary dysplasia. J. Pediatr. 2014; 165 : 1258-1260
  15. Kim HR, Kim JY, Yun B, Lee B, Choi CW, Kim BL. Interstitial pnuemonia pattern on day 7 chest radiograph predicts bronchopulmonary dysplasia in preterm infants. BMC. Pediatr . 2017; 17 :125.
  16. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR, A simulation study of the number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology . 1996; 49 (12): 1373–1379.
  17. Cuna A, Lewis T, Dai H, Nyp M, Truog W. Timing of postnatal corticosteriod treatment for bronchopulmonary dysplasia and its effect on outcomes. Pediatric. Pulmonol . 2019; 54: 165-170